Ziprasidone 사용 후 발생한 호중구감소증

Ziprasidone Induced Neutropenia

  몇몇 항정신병 약물들은 호중구감소증을 일으킬 위험이 있는 것으로 알려져 왔다. 본 증례에서는 정신분열병의 치료를 위해 ziprasidone을 복용한 후 호중구감소증이 발생되었고, ziprasidone 복약 중단 후 호중구감소증이 회복된 35세 여자 환자를 보고한다. 본 증례에서 나타난 호중구감소증은 ziprasidone의 복용과 관계된 것으로 판단된다. 따라서 ziprasidone의 투약시 호중구감소증의 발생 가능성에 대해서 유의해야 하며, 이에 대한 임상가들의 주지와 체계적인 연구가 필요하다고 본다.

  Neutropenia and agranulocytosis are dangerous conditions seldom caused by antipsychotics. We report the case of a 35-year-old female patient who presented with neutropenia following ziprasidone administration. Ziprasidone was gradually increased to 160 ㎎/day in combination with escitaloprarn 10 ㎎/day. Following ziprasidone administration, her neutrophil count fell to 1700×10³/㎣, on day 45 and to 1500×10³/㎣ on day 57. Ziprasidone was immediately stopped, and quetiapine 25 ㎎ was given from the next day onward, along with the escitaloprarn. Her neutrophil count rose to 2700×10³/㎣ 2 days later, and was maintained at 2,900×10³/㎣ at 17 days after changing medication. To the best of our knowledge, this case represents the first report of ziprasidoneinduced neutropenia in Korea. Further study is necessary to determine the incidence of neutropenia and its relationship with agranulocytosis secondary to ziprasidone.